Sun Pharmaceutical Industries Limited
Clinical trials sponsored by Sun Pharmaceutical Industries Limited, explained in plain language.
A major Indian multinational pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes drug studied in kidney patients Results expected Sep 2026 (estimated)
- Can a reformulated gel plus light therapy better tackle precancerous skin spots? Results expected Dec 2026 (estimated)
- New weekly shot shows promise for diabetes and weight loss Results expected Apr 2027 (estimated)
-
New hope for kids with severe psoriasis: drug trial shows promise
Disease control OngoingThis study tests a drug called tildrakizumab in children aged 6 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it safely reduces skin symptoms like redness and scaling. Participants receive the drug or a placebo, and researchers monitor results over time. S…
Phase 2/3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug shows promise for psoriatic arthritis in major trial
Disease control OngoingThis phase 3 study tests whether tildrakizumab, an injected drug, can reduce joint pain and swelling in people with active psoriatic arthritis who have not used anti-TNF treatments before. About 296 adults will receive either the drug or a placebo. The main goal is to see if at l…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for psoriatic arthritis: tildrakizumab shows promise in Long-Term trial
Disease control OngoingThis phase 3 study is testing the long-term safety and effectiveness of tildrakizumab, a biologic drug given as an injection, in people with psoriatic arthritis. Researchers are tracking side effects and how well the drug reduces joint pain, swelling, and other symptoms over time…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Acne cream aims to shrink oil glands in new study
Disease control OngoingThis study tests whether a cream called clascoterone (Winlevi) can shrink oil glands and change the oil on the face in people with acne. Ten adults with oily skin and moderate acne will use the cream twice daily for 3 months. Researchers will take small skin samples to see if the…
Phase 4 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Promising drug may ease painful genital psoriasis
Symptom relief OngoingThis study tests an injected drug called tildrakizumab for people with moderate to severe genital psoriasis. About 206 adults will receive either the drug or a placebo to see if it clears skin and reduces itching. The goal is to improve comfort and quality of life in this sensiti…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC